New psoriasis pill shows promise in Mid-Stage trial
NCT ID NCT07251998
First seen Dec 29, 2025 · Last updated Jun 11, 2026 · Updated 26 times
Summary
This study tests an experimental drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. The main goal is to see if more people achieve a 75% improvement in their psoriasis symptoms after 12 weeks of treatment. Participants must have had psoriasis for at least 6 months and meet specific severity criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Dermatology Hospital
RECRUITINGShanghai, Shanghai Municipality, 200443, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.